Minnesota Glomerular Disease Program

Mission

Provide expert, individualized care to patients with any glomerular disease, with ongoing Phase 2 and Phase 3 clinical trials in Focal Segmental Glomerulosclerosis (FSGS) and IgA Nephropathy. For more information, email [email protected]

Covered Diseases

  • Focal Segmental Glomerulosclerosis (FSGS)
  • Membranous nephropathy
  • Minimal change disease 
  • IgA nephropathy
  • Immune complex mediated diseases
  • C3 Glomerulopathy
  • Fibrillary Glomerular Disease
  • Cryoglobulinemia
  • Anti-Glomerular Basement Membrane (anti-GBM) Disease
  • Alport Syndrome
  • Thin basement membrane disease
  • Vasculitis
  • Lupus Nephritis
  • For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage

Goals

  • Provide expert care for patients with glomerular disease.
  • Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
  • Provide patients with access to cutting-edge clinical trials.
  • Facilitate translational research.
  • Provide a venue for health care providers training in the care of patients with glomerular disease. 

Highlights

  • September 2023: Enrolled the 60th patient into the registry. 

Our Team

Physicians

Research Team

  • Amy Hanson, CCRC, Clinical Research Coordinator, Pediatrics
  • Anael Kuperwajs Cohen, CCRC, Clinical Research Coordinator, Pediatrics
  • Scott Rajala, CCRP, Clinical Research Coordinator

Ongoing Clinical Trials

Expand all

Anti-GBM

A Phase 3 Open-label, Controlled, Randomised, Multi-centre Trial Comparing Imlifidase and Standard-of-care With Standard-of-care Alone in the Treatment of Severe Anti-GBM Antibody Disease (Goodpasture Disease)

Principal Investigator
Patrick Nachman, MD

Co-Investigators
Andrew Johnson, MD
Nattawat Klomjit, MD
Sahar Koubar, MBBS
Aahd Kubbara, MD
Katie Pendleton, MD
Sami Safadi, MD

Study Coordinator
Nicolas Rauwolf | 
[email protected]

CLINICAL TRIAL

Focal Segmental Glomerulosclerosis (FSGS)

The Nephrotic Syndrome Study Network (NEPTUNE)

Principal Investigator:
Patrick Nachman, MD

Co-Principal Investigators: 
Michelle Rheault, MD
Angie Lobo, MD

Study Coordinators: 
Scott Rajala, CCRP | 
[email protected]
Nicolas Rauwolf | 
[email protected]

CLINICAL TRIAL

IgA Nephropathy

New Study Starting Soon! 

Membranoproliferative Glomerulonephritis

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Idiopathic Immune Complex Mediated Membranoproliferative Glomerulonephritis (IC-MPGN)

Principal Investigator
Nattawat Klomjit, MD 

Co-Investigators
Patrick H. Nachman, MD

Study Coordinator:
Nicolas Rauwolf | 
[email protected]

CLINICAL TRIAL

Membranous Nephropathy

Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)

Principal Investigator
Patrick Nachman, MD

Co-Investigator
Surabhi Thakar, MD
Katti Woerner, MD

Study Coordinators
Nicolas Rauwolf | 
[email protected]

CLINICAL TRIAL

The Nephrotic Syndrome Study Network (NEPTUNE)

Principal Investigator: 
Patrick Nachman, MD

Co-Principal Investigators: 
Michelle Rheault, MD
Angie Lobo, MD

Study Coordinators: 
Scott Rajala, CCRP | 
[email protected]
Nicolas Rauwolf | 
[email protected]

CLINICAL TRIAL